{"id":"https://genegraph.clinicalgenome.org/r/02212618-0725-43db-9a4c-7929faeb878av1.0","type":"EvidenceStrengthAssertion","dc:description":"*STXBP2* was first reported in relation to autosomal recessive familial hemophagocytic lymphohistiocytosis 5 (FHL5) in 2009 (zur Stadt U, et al., 2009, PMID: 19804848). FHL is a hyperinflammatory syndrome caused by an uncontrolled and ineffective proliferation and activation of T lymphocytes, natural killer (NK) cells, and macrophages that infiltrate multiple organs, including liver, spleen, lymph nodes, and central nervous system (CNS), and produce massive amounts of cytokines. This overwhelming hyperimmune status results in a clinical picture characterized by persistent fever, hepatosplenomegaly, pancytopenia, hemophagocytosis in various tissues, coagulation abnormalities, and inflammatory CNS disease. Patients with FHL5 have several unique features, including sensorineural hearing deficit, abnormal bleeding, and severe diarrhea. *STXBP2* is involved in intracellular vesicle trafficking and vesicle fusion with membranes, it contributes to the granule exocytosis machinery through interaction with soluble N-ethylmaleimide-sensitive factor attachment protein receptor proteins that regulate membrane fusion. The role of *STXBP2* in the cytotoxic granule pathway, and how variation in the gene results in FHL5 is currently not understood in detail but the mechanism of disease appears to be loss of function. This curation includes eleven variants (including in-frame deletions, missense, splicing, and frameshift) found in ten probands from two publications (PMIDs: 19804848, 22451424). Additional cases are available in the literature however the maximum score for genetic evidence has been reached. A role in disease is supported by increased expression of *STXBP2* in NK cells, T cells, monocytes, and other hematopoietic cells (PMID: 19804848), which is altered in patients (PMID: 19884660), resulting in altered cytotoxicity of patient NK cells and cytotoxic T-lymphocytes (PMID: 19804848). Additionally, degranulation defects were rescued in patient cells with wildtype *STXBP2* (PMID: 19884660). *STXBP2* is also known to interact with *STX11*, which has a well established relationship with FHL (PMID: 19804848). In summary *STXBP2* is definitively associated with autosomal recessive FHL5. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time.","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/02212618-0725-43db-9a4c-7929faeb878a","GCISnapshot":"https://genegraph.clinicalgenome.org/r/0b5c9256-89e0-4f97-a7ca-dd07bdd237f9","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/0b5c9256-89e0-4f97-a7ca-dd07bdd237f9_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10145","date":"2023-09-19T12:45:32.254Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/0b5c9256-89e0-4f97-a7ca-dd07bdd237f9_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10145","date":"2023-09-19T16:00:00.000Z","role":"Approver"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0b5c9256-89e0-4f97-a7ca-dd07bdd237f9_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/54398a40-c0de-4902-9a09-430425a9a2a6_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b67b8a19-1578-4511-aa2b-339af88e2d1d","type":"EvidenceLine","dc:description":"The frameshift variant introduces a premature stop codon in exon 6 of 19 and is predicted to cause NMD.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b67b8a19-1578-4511-aa2b-339af88e2d1d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19804848","allele":{"id":"https://genegraph.clinicalgenome.org/r/7e58c452-2802-4eec-a0d6-bf3db66eb01b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006949.4(STXBP2):c.260del (p.Leu87ArgfsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA913185061"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/56583742-88e6-4dae-a1b1-c0e7cf3ecdd2","type":"EvidenceLine","dc:description":"Analysis of patient RNA revealed a deletion of exon 15 (of 19) resulting in a frameshift and 126 new codons, with a premature stop codon in the penultimate exon, as a major event (p.Val417LeufsX126) but also a variety of other, including in-frame, products.\n\nPopmax filtering allele frequency 0.0002829 from gnomADv2.1.1 European (non-Finnish) population.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/56583742-88e6-4dae-a1b1-c0e7cf3ecdd2_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"From PMID: 22451424 -- An exogenous construct made with cDNA that harbors the c.1247-1356 deletion of the complete 110 nucleotides of exon 15, resulting in a premature stop (p.Val417LeuTer126) was used for coimmunoprecipitation analysis for binding with syntaxin 11. Weak binding was found compared to WT.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/56583742-88e6-4dae-a1b1-c0e7cf3ecdd2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19804848","allele":{"id":"https://genegraph.clinicalgenome.org/r/72aa46ef-9d56-4499-b144-db94f06d8485","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006949.4(STXBP2):c.1247-1G>C","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA9144081"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/54398a40-c0de-4902-9a09-430425a9a2a6","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19804848","rdfs:label":"2290","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":15,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/7e58c452-2802-4eec-a0d6-bf3db66eb01b"},{"id":"https://genegraph.clinicalgenome.org/r/72aa46ef-9d56-4499-b144-db94f06d8485"}],"detectionMethod":"Whole-genome homozygosity mapping. STXBP2 was then PCR amplified and there was Sanger sequencing of coding exons and adjacent intronic sequences.","firstTestingMethod":"Homozygosity mapping","phenotypeFreeText":"CNS involvement, death at 7 years due to multiorgan failure","previousTestingDescription":"Screened for mutations in PRF1, UNC13D, and STX11.","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/56583742-88e6-4dae-a1b1-c0e7cf3ecdd2_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/b67b8a19-1578-4511-aa2b-339af88e2d1d_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/377b7b1c-f5f9-45e4-9fe6-00fb1611d2d8_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/033fe9b8-428d-4713-a2ab-b6c6a727b072","type":"EvidenceLine","dc:description":"Found in gnomADv2.1.1 at popmax filtering allele frequency of 0.0003645 based on the European (non-Finnish) population.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/033fe9b8-428d-4713-a2ab-b6c6a727b072_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"An exogenous construct made with cDNA that harbors the c.1621G>A mutation, resulting in Gly541Ser was used for coimmunoprecipitation analysis for binding with syntaxin 11. Weak binding was found compared to WT.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/033fe9b8-428d-4713-a2ab-b6c6a727b072_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22451424","allele":{"id":"https://genegraph.clinicalgenome.org/r/8ec26f5a-5fda-429d-900d-04a5d7c42ea6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006949.4(STXBP2):c.1621G>A (p.Gly541Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA260033"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/0450ad7c-facb-4d3b-af19-94b957541014","type":"EvidenceLine","dc:description":"This splice variant is predicted to cause skipping of exon 2 (of 19) causing a frameshift and premature stop codon in exon 3 which may lead to NMD.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0450ad7c-facb-4d3b-af19-94b957541014_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22451424","allele":{"id":"https://genegraph.clinicalgenome.org/r/08e64423-8984-4dac-b994-caf0d9485c11","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006949.4(STXBP2):c.87+2T>C","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA403155275"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/377b7b1c-f5f9-45e4-9fe6-00fb1611d2d8","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22451424","rdfs:label":"A-376","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":2,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/08e64423-8984-4dac-b994-caf0d9485c11"},{"id":"https://genegraph.clinicalgenome.org/r/8ec26f5a-5fda-429d-900d-04a5d7c42ea6"}],"detectionMethod":"PCR amplification of genomic DNA for all exons and adjacent intronic sequences followed by Sanger sequencing.","firstTestingMethod":"Sanger sequencing","phenotypes":"obo:HP_0000407","previousTestingDescription":"biallelic mutations in PRF, UNC13D, and STX11 were excluded","sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/033fe9b8-428d-4713-a2ab-b6c6a727b072_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/0450ad7c-facb-4d3b-af19-94b957541014_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.0},{"id":"https://genegraph.clinicalgenome.org/r/e45f3818-1b59-43a4-81e8-c485d990c1b1_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1da8c415-dd06-47de-b10a-c2d7df33a063","type":"EvidenceLine","dc:description":"The variant is homozygous by consanguinity.","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1da8c415-dd06-47de-b10a-c2d7df33a063_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"From PMID: 22451424 -- An exogenous construct made with cDNA that harbors the c.1247-1356 deletion of the complete 110 nucleotides of exon 15, resulting in a premature stop (p.Val417LeuTer126) was used for coimmunoprecipitation analysis for binding with syntaxin 11. Weak binding was found compared to WT.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/1da8c415-dd06-47de-b10a-c2d7df33a063_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19804848","allele":{"id":"https://genegraph.clinicalgenome.org/r/72aa46ef-9d56-4499-b144-db94f06d8485"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/e45f3818-1b59-43a4-81e8-c485d990c1b1","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19804848","rdfs:label":"0879","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":28,"allele":{"id":"https://genegraph.clinicalgenome.org/r/72aa46ef-9d56-4499-b144-db94f06d8485"},"detectionMethod":"Whole-genome homozygosity mapping. STXBP2 was then PCR amplified and there was Sanger sequencing of coding exons and adjacent intronic sequences.","firstTestingMethod":"Homozygosity mapping","phenotypeFreeText":"5/5 HLH criteria met","phenotypes":["obo:HP_0001744","obo:HP_0030396","obo:HP_0002088","obo:HP_0020072","obo:HP_0004313"],"previousTestingDescription":"Screened for mutations in PRF1, UNC13D, and STX11.","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/1da8c415-dd06-47de-b10a-c2d7df33a063_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/9a9b78a9-fdd3-4b48-8549-46653004b540_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a99c4422-127c-45fe-a1f7-280286bc6c66","type":"EvidenceLine","dc:description":"This frameshift variant in exon 5 (of 19) creates a premature stop codon in exon six predicted to result in NMD.\n\nhomozygous by consanguinity","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a99c4422-127c-45fe-a1f7-280286bc6c66_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22451424","allele":{"id":"https://genegraph.clinicalgenome.org/r/5be24c66-9727-4cd9-851d-1a82a235ce28","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006949.4(STXBP2):c.279del (p.Thr94ProfsTer25)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2580617412"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/9a9b78a9-fdd3-4b48-8549-46653004b540","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22451424","rdfs:label":"A_724","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":2,"allele":{"id":"https://genegraph.clinicalgenome.org/r/5be24c66-9727-4cd9-851d-1a82a235ce28"},"detectionMethod":"PCR amplification of genomic DNA for all exons and adjacent intronic sequences followed by Sanger sequencing.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"CNS involvement, death at 1.2y due to HLH with multiorgan failure","previousTestingDescription":"biallelic mutations in PRF, UNC13D, and STX11 were excluded","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/a99c4422-127c-45fe-a1f7-280286bc6c66_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/57fdec86-b309-4c84-9f86-0ca0b3307ce1_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2c1ff7e4-8de8-4635-9d9b-f819e8d50ef1","type":"EvidenceLine","dc:description":"Homozygous due to consanguinity.\n\n0.00007368 popmax filtering allele frequency from the gnomADv2.1.1 South Asian population","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2c1ff7e4-8de8-4635-9d9b-f819e8d50ef1_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Using site-directed mutagenesis, the authors showed that this variant lead to a complete loss of the ability to bind to syntaxin 11.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/2c1ff7e4-8de8-4635-9d9b-f819e8d50ef1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19804848","allele":{"id":"https://genegraph.clinicalgenome.org/r/4f4553fc-7191-4d8b-b88e-d2748e1a1423","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006949.4(STXBP2):c.1214G>A (p.Arg405Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA9144031"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/57fdec86-b309-4c84-9f86-0ca0b3307ce1","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19804848","rdfs:label":"1949","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":3,"allele":{"id":"https://genegraph.clinicalgenome.org/r/4f4553fc-7191-4d8b-b88e-d2748e1a1423"},"detectionMethod":"Whole-genome homozygosity mapping. STXBP2 was then PCR amplified and there was Sanger sequencing of coding exons and adjacent intronic sequences.","firstTestingMethod":"Homozygosity mapping","previousTestingDescription":"Screened for mutations in PRF1, UNC13D, and STX11.","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/2c1ff7e4-8de8-4635-9d9b-f819e8d50ef1_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/1858337f-34fc-4ff5-bed8-7add17f83593_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/10fc1c50-2ac4-4609-a1ee-89472e546cd3","type":"EvidenceLine","dc:description":"homozygous due to consanguinity","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/10fc1c50-2ac4-4609-a1ee-89472e546cd3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19804848","allele":{"id":"https://genegraph.clinicalgenome.org/r/587de1a7-c886-4c0c-9581-802632767e31","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006949.4(STXBP2):c.693_695del (p.Ile232del)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA913185062"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/1858337f-34fc-4ff5-bed8-7add17f83593","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19804848","rdfs:label":"1155","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":2,"allele":{"id":"https://genegraph.clinicalgenome.org/r/587de1a7-c886-4c0c-9581-802632767e31"},"detectionMethod":"Whole-genome homozygosity mapping. STXBP2 was then PCR amplified and there was Sanger sequencing of coding exons and adjacent intronic sequences.","firstTestingMethod":"Homozygosity mapping","phenotypeFreeText":"5/5 HLH criteria met, central nervous system involvement","previousTestingDescription":"Screened for mutations in PRF1, UNC13D, and STX11.","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/10fc1c50-2ac4-4609-a1ee-89472e546cd3_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/5d76c7de-d884-409c-858d-a9c7995aa5cf_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3ad9ddfd-399f-4820-905c-31f24c0a72be","type":"EvidenceLine","dc:description":"Variant is homozygous due to consanguinity.\n\nPresent in gonmADv2.1.1 in 1/19252 alleles in the East Asian population.","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3ad9ddfd-399f-4820-905c-31f24c0a72be_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Using site-directed mutagenesis, the authors showed that this variant lead to a complete loss of the ability to bind to syntaxin 11.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/3ad9ddfd-399f-4820-905c-31f24c0a72be_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19804848","allele":{"id":"https://genegraph.clinicalgenome.org/r/ce6508ac-b270-4f95-a36a-a356ecdb286f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006949.4(STXBP2):c.1430C>T (p.Pro477Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA254261"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/5d76c7de-d884-409c-858d-a9c7995aa5cf","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19804848","rdfs:label":"1875","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":4,"allele":{"id":"https://genegraph.clinicalgenome.org/r/ce6508ac-b270-4f95-a36a-a356ecdb286f"},"detectionMethod":"Whole-genome homozygosity mapping. STXBP2 was then PCR amplified and there was Sanger sequencing of coding exons and adjacent intronic sequences.","firstTestingMethod":"Homozygosity mapping","phenotypeFreeText":"5/8 HLH criteria met","phenotypes":"obo:HP_0004313","previousTestingDescription":"Screened for mutations in PRF1, UNC13D, and STX11.","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/3ad9ddfd-399f-4820-905c-31f24c0a72be_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/6469faee-4be8-41c3-8daa-880f5828c657_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/87ad891e-c0bc-404d-9340-77e277e96175","type":"EvidenceLine","dc:description":"Homozygous due to consanguinity.\n\ngnomadV2.1.1 popmax filtering allele frequency 0.00001082","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/87ad891e-c0bc-404d-9340-77e277e96175_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Using site-directed mutagenesis, the authors showed that this variant lead to a complete loss of the ability to bind to syntaxin 11.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/87ad891e-c0bc-404d-9340-77e277e96175_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19804848","allele":{"id":"https://genegraph.clinicalgenome.org/r/2e51d7d1-3f35-4af3-b53d-3a735248bf59","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006949.4(STXBP2):c.1213C>T (p.Arg405Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA9144030"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/6469faee-4be8-41c3-8daa-880f5828c657","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19804848","rdfs:label":"1948","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":9,"allele":{"id":"https://genegraph.clinicalgenome.org/r/2e51d7d1-3f35-4af3-b53d-3a735248bf59"},"detectionMethod":"Whole-genome homozygosity mapping. STXBP2 was then PCR amplified and there was Sanger sequencing of coding exons and adjacent intronic sequences.","firstTestingMethod":"Homozygosity mapping","previousTestingDescription":"Screened for mutations in PRF1, UNC13D, and STX11.","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/87ad891e-c0bc-404d-9340-77e277e96175_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/c61897d6-4ef8-4ea6-be8c-de5060906843_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6f430549-9a1e-4712-971b-39d8817abf5d","type":"EvidenceLine","dc:description":"Analysis of patient RNA revealed a deletion of exon 15 (of 19) resulting in a frameshift and 126 new codons, with a premature stop codon in the penultimate exon, as a major event (p.Val417LeufsX126) but also a variety of other, including in-frame, products.\n\nWestern blot analysis of lymphoblasts showed residual Munc18-2 protein with a slightly reduced molecular weight (PMID: 22451424).\n\nPopmax filtering allele frequency 0.0002829 from gnomADv2.1.1 European (non-Finnish) population.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6f430549-9a1e-4712-971b-39d8817abf5d_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"From PMID: 22451424 -- An exogenous construct made with cDNA that harbors the c.1247-1356 deletion of the complete 110 nucleotides of exon 15, resulting in a premature stop (p.Val417LeuTer126) was used for coimmunoprecipitation analysis for binding with syntaxin 11. Weak binding was found compared to WT.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/6f430549-9a1e-4712-971b-39d8817abf5d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19804848","allele":{"id":"https://genegraph.clinicalgenome.org/r/72aa46ef-9d56-4499-b144-db94f06d8485"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/3609e8f4-4f85-47b2-bdde-50b442dbd04b","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3609e8f4-4f85-47b2-bdde-50b442dbd04b_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Using site-directed mutagenesis, the authors showed that this variant lead to a complete loss of the ability to bind to syntaxin 11.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/3609e8f4-4f85-47b2-bdde-50b442dbd04b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19804848","allele":{"id":"https://genegraph.clinicalgenome.org/r/7187de37-33b4-4829-9d4f-26d24a67b3f7","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006949.4(STXBP2):c.626T>C (p.Leu209Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA254263"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/c61897d6-4ef8-4ea6-be8c-de5060906843","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19804848","rdfs:label":"0870","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":28,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/7187de37-33b4-4829-9d4f-26d24a67b3f7"},{"id":"https://genegraph.clinicalgenome.org/r/72aa46ef-9d56-4499-b144-db94f06d8485"}],"detectionMethod":"Whole-genome homozygosity mapping. STXBP2 was then PCR amplified and there was Sanger sequencing of coding exons and adjacent intronic sequences.","firstTestingMethod":"Homozygosity mapping","phenotypeFreeText":"5/5 HLH criteria met, central nervous system involvement","phenotypes":["obo:HP_0000407","obo:HP_0004313"],"previousTestingDescription":"Screened for mutations in PRF1, UNC13D, and STX11.","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/3609e8f4-4f85-47b2-bdde-50b442dbd04b_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/6f430549-9a1e-4712-971b-39d8817abf5d_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.0},{"id":"https://genegraph.clinicalgenome.org/r/ce3f7d4b-61a5-48bd-bea2-1c58760dac10_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a7078fab-b496-4736-9816-dcfbbbba013d","type":"EvidenceLine","dc:description":"This variant is homozygous due to consanguinity.\nPresent in gnomADv2.1.1 in 1/16252 alleles in the African/African American population.","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a7078fab-b496-4736-9816-dcfbbbba013d_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Using site-directed mutagenesis, the authors showed that this variant lead to a complete loss of the ability to bind to syntaxin 11.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/a7078fab-b496-4736-9816-dcfbbbba013d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19804848","allele":{"id":"https://genegraph.clinicalgenome.org/r/9ad6ef1d-1d45-4cb0-84aa-b808e85b2551","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006949.4(STXBP2):c.875G>A (p.Arg292His)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA9143827"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/ce3f7d4b-61a5-48bd-bea2-1c58760dac10","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19804848","rdfs:label":"0884","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":2,"allele":{"id":"https://genegraph.clinicalgenome.org/r/9ad6ef1d-1d45-4cb0-84aa-b808e85b2551"},"detectionMethod":"Whole-genome homozygosity mapping. STXBP2 was then PCR amplified and there was Sanger sequencing of coding exons and adjacent intronic sequences.","firstTestingMethod":"Homozygosity mapping","phenotypeFreeText":"CNS involvement, transplant associated hemorrhagic mucositis","phenotypes":["obo:HP_0100309","obo:HP_0001892"],"previousTestingDescription":"Screened for mutations in PRF1, UNC13D, and STX11.","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/a7078fab-b496-4736-9816-dcfbbbba013d_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/0b5c9256-89e0-4f97-a7ca-dd07bdd237f9_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0b5c9256-89e0-4f97-a7ca-dd07bdd237f9_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0bddba09-a727-4eae-b57d-b4572cde55f5","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/11636c41-eacb-413f-9553-de5a9bc26e72","type":"Finding","dc:description":"NK cells were cotransfected with the cDNA encoding WT STXBP2 and an otherwise empty fluorescent vector. Degranulation was restored in the fraction of patientsâ€™ NK cells that had been cotransfected, while it remained impaired in NK cells transfected with the empty vector alone.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19884660","rdfs:label":"NK cell rescue","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityPatientCellRescueCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/0b5c9256-89e0-4f97-a7ca-dd07bdd237f9_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c8a30fc6-e5ce-49c1-8d68-d3b634516f37","type":"EvidenceLine","dc:description":"The pronounced and sustained immune dysregulation in FHL is caused mainly by defects in cellular cytotoxicity, which is required not only for pathogen control but also for immune homeostasis. In the absence of a negative feedback signal, continuous stimulation of T cells and subsequent activation of macrophages lead to the characteristic hypercytokinemia and fatal organ infiltrations. Functional tests in NK cells and CTLs from our FHL-5 patients underline these findings. The authors showed a severe reduction of both the degranulation capacity and the capacity to kill target cells.\n\nThe exact function of STXBP2 within the secretory machinery of immune cells is still not well understood. From previous studies, it is known that STXBP2 is important for controlling intracellular granule/membrane trafficking in polarized epithelial cells, neutrophils, and mast cells (PMIDS: 12482918, 12198139, 18588921). ","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d6725d95-7a53-4615-932b-2abe08e64eb9","type":"FunctionalAlteration","dc:description":"In order to assess the cytotoxic capacities in FHL-5 cases the authors analyzed degranulation and cytotoxicity of natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs) in two early-onset and three late-onset patients with STXBP2 mutations. They measured NK cell and T cell degranulation after stimulation of intracellular granule exocytosis by extracellular staining of CD107 in four patients. CD107 was absent in three of the patients and in the lower normal range in one late-onset patient. Ex vivo cytotoxicity on NK cell-sensitive K562 targets was impaired in all five patients tested. CTL degranulation was low in phytohaemagglutinin blasts from all patients analyzed. Additionally, CTL cytotoxicity was very low in two early-onset patients but in the lower normal range in three late-onset patients.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19804848","rdfs:label":"Cytotoxicity"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/0b5c9256-89e0-4f97-a7ca-dd07bdd237f9_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/28ee0553-bf7d-4c8f-aa6a-9e370018a8c0","type":"EvidenceLine","dc:description":"Variation in STX11 is a well-established cause of hemophagacytic lymphohistiocytosis.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/eb2ee438-d735-437a-88de-6273aa365f7b","type":"Finding","dc:description":"Coimmunoprecipitation demonstrated shared binding sites between STXBP2 and STX11.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19804848","rdfs:label":"STX11 interaction","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/414247d3-2dc9-4970-a78a-3dd12caef7e0","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9ff05c49-f0b1-42ca-897f-f570f15bc4bb","type":"Finding","dc:description":"The authors assessed the expression of STXBP2 in lymphoblasts obtained from F2P1, F2P2, F5P1, and F6P1. In a protein blot analysis, STXBP2 protein was not found in lymphoblasts from F2P1 or F2P2 but was detected in lymphoblasts from F5P1 and F6P1, albeit at markedly lower levels than in control lymphoblasts.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19884660","rdfs:label":"Altered expression in lymphocytes","demonstrates":{"id":"cg:GeneExpressionB"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/bc3ce7e9-bc9f-4b4e-9145-88b9f29451a4","type":"EvidenceLine","dc:description":"Consistent with enhanced expression in lymphoid tissue reported in the Human Protein Atlas.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/07ace2fb-62ab-47c0-a217-e87ae9f30ec1","type":"Finding","dc:description":"Relative quantification of STXBP2 was measured in various human tissues by real-time PCR. Expression was particularly high in NK cells, T cells, monocytes, and other hematopoietic cells.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19804848","rdfs:label":"increased expression in hematopoietic cells","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":3.5}],"evidenceStrength":"Definitive","sequence":6891,"specifiedBy":"GeneValidityCriteria9","strengthScore":15.5,"subject":{"id":"https://genegraph.clinicalgenome.org/r/NW4PbREKHCg","type":"GeneValidityProposition","disease":"obo:MONDO_0013135","gene":"hgnc:11445","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_0b5c9256-89e0-4f97-a7ca-dd07bdd237f9-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}